Advanced Biotherapy's CEO Asked to Join U.S. Representative Roscoe Bartlett and Scientific Delegation in Taiwan.Business Editors/Health/Medical Writers TAIPEI, Taiwan--(BUSINESS WIRE)--Nov. 21, 2003 Advanced Biotherapy biotherapy /bio·ther·a·py/ (-ther´ah-pe) biological therapy. bi·o·ther·a·py n. Treatment of disease with biologicals, such as vaccines. , Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ADVB ADVB Associação dos Dirigentes de Vendas e Marketing do Brasil ) and the Office of United States Congressman Roscoe Bartlett issued the following joint press release: -- Edmond Buccellato Joins Delegation in Furtherance of Promoting Free Trade Agreement Negotiations between United States and Taiwan Advanced Biotherapy, Inc. (OTCBB:ADVB), a developer of antibody therapies to treat severe autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , reported today that Edmond Buccellato, Chief Executive Officer and Chairman of the Board of Directors, has joined a team of U.S. business executives, at the request of United States Congressman Roscoe Bartlett (R-MD), to meet in Taiwan with representatives of the country's Ministry of Economic Affairs The following nations have a Ministry of Economic Affairs:
Mr. Buccellato stated, "I am honored to serve on this delegation to develop international biotechnology relationships between the United States and Taiwan. Our country's pool of scientific and business talent in biotechnology has resulted in novel and effective treatments for a host of medical needs -- achievements that are unparalleled in the world. Taiwan's emergence as a vibrant and innovative biotechnology hub for the Pacific Rim creates an opportunity to forge scientific alliances that may be commercially attractive for both countries, and more importantly, result in continued and effective development of medical treatments for those who suffer from life-threatening and catastrophic diseases throughout the world. We look forward to productive and fruitful discussions while we are guests in this very progressive country." Congressman Bartlett stated, "I want to thank Mr. Buccellato for joining this delegation. His Company's experience and boldness under the direction of their Senior Scientist, Dr. Simon Skurkovich, in cultivating international biotechnology relationships in Eastern Europe is very encouraging. The purpose of this visit is to demonstrate the vast economic interest and mutual benefits the State of Maryland and the United States offers to business, industry and investors from Taiwan. Promoting knowledge of the astonishing a·ston·ish tr.v. as·ton·ished, as·ton·ish·ing, as·ton·ish·es To fill with sudden wonder or amazement. See Synonyms at surprise. array of scientific and entrepreneurial talent and the outstanding and educated work force in western Maryland among leading biotech businesses, such as Advanced Biotherapy, Inc., to our allies in Taiwan will help create more job opportunities. I am confident that this effort will also further strengthen the potential for successful negotiations of a U.S.-Taiwan Free Trade Agreement." About Advanced Biotherapy Advanced Biotherapy, Inc., located in Los Angeles, with research laboratories in Columbia, Md., is pioneering the development of new antibody therapies for treating severe and widespread autoimmune diseases. Its investigational antibody therapies attack autoimmune diseases at their source, neutralizing biologic imbalances that impair immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. function. The Company's approach to treating autoimmune diseases has shown encouraging and sometimes striking results in investigational clinical trials in rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. , multiple sclerosis, various skin diseases (including psoriasis, alopecia areata alopecia ar·e·a·ta n. Hair loss in circumscribed, noninflamed areas of the scalp, eyebrows and beard. Also called alopecia circumscripta. , vitiligo vitiligo or leukoderma Skin disorder manifested by smooth, white spots on various parts of the body. Though the pigment-making cells of the skin, or melanocytes, are structurally intact, they have lost the ability to synthesize the pigment. , pemphigus pemphigus /pem·phi·gus/ (-gus) 1. a distinctive group of diseases marked by successive crops of bullae. 2. pemphigus vulgaris. and epidermolysis bullosa Epidermolysis Bullosa Definition Epidermolysis bullosa (EB) is a group of rare inherited skin diseases that are characterized by the development of blisters following minimal pressure to the skin. ), type 1 diabetes type 1 diabetes n. See diabetes mellitus. and corneal transplant rejection. Core technology is protected under U.S. patents and patents pending for the exclusive use of a class of antibodies to the protein known as interferon-gamma and antibodies to other proteins, such as tumor necrosis factor-alpha Tumor necrosis factor (TNF, cachexin or cachectin and formally known as tumor necrosis factor-alpha) is a cytokine involved in systemic inflammation and is a member of a group of cytokines that all stimulate the acute phase reaction. , for treating a range of autoimmune diseases. Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the anticipated results or other expectations expressed in our forward-looking statements. Some of these forward-looking statements may be identified by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. The risks and uncertainties which may affect the development, operations and results of our business include, but are not limited to, the following: risks associated with clinical trials, the uncertainties of research and product development programs, the uncertainties of the regulatory approval process, the risks of competitive products, the risks of our current capital resources, the uncertainties as to the availability of future capital and our future capital requirements, and the risks associated with the extent and breadth of the Company's patent portfolio. The foregoing discussion of the pending clinical investigations and the effect of the patents issued and pending involve risks and uncertainties, including, but not limited to, the risks that third parties may be successful in challenging such patents, or that granted claims may be held invalid or interpreted differently by a court of law, or that new technologies will be developed that are superior in treating the diseases targeted by Advanced Biotherapy, Inc. Readers are cautioned not to place reliance on these forward-looking statements, which speak only as of the date the statements were made. See the Company's public filings with the Securities and Exchange Commission for further information about risks and uncertainties that may affect the Company and the results or expectations expressed in our forward-looking statements, including the section captioned "Factors That May Affect The Company," contained in the Company's Annual Report on Form 10-KSB/A for the fiscal year ended December 31, 2002. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion